Get Thin MD vs K Health
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Get Thin MD
Best for lowest-priced compounded semaglutide on a 3-month commitment, with brand-name Ozempic/Zepbound also availableStarting at $169/mo
K Health
Best for users who want general primary care with GLP-1 prescribing as one available option, not a single-condition weight-loss funnelStarting at $300/mo
Side-by-Side Comparison
| Feature | Get Thin MD | K Health |
|---|---|---|
| Overall Score | ✓7.9/10 | 6.6/10 |
| Starting Price | ✓$169/mo | $300/mo |
| Editorial Rating | ✓4 ★ /5 | 3.3 ★ /5 |
| Features | ✓7 features | 4 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | — |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Get Thin MD
Pros
- ✓3-month compounded semaglutide plan at $169/month is one of the lowest ongoing prices in the compounded GLP-1 category
- ✓Price-lock positioning: 'Same price, every dose. No hidden fees.' — per the product page
- ✓Both compounded and brand-name options available in one platform (compounded semaglutide, compounded tirzepatide, plus brand-name Ozempic and Zepbound where medically appropriate)
- ✓Nationwide availability with async evaluation — no in-person visit required
- ✓Broader wellness platform that also offers sermorelin, NAD+, HRT, and hair-loss treatments, so patients can consolidate multiple protocols with one provider
- ✓Proper FDA compounding disclaimer on the product page: "The FDA does not review or approve any compounded medications for safety or effectiveness."
Cons
- ✗Compounded medications are not FDA-approved as finished products and lack the formal safety/efficacy review of brand-name Ozempic, Wegovy, Zepbound, and Mounjaro
- ✗Pharmacy partners not publicly named on the site — no independent way to verify 503A/503B compounding source or per-batch testing
- ✗State-by-state availability claimed as nationwide but no verbatim state list is published — needs intake signup to confirm whether every state is actually served
- ✗Clinical efficacy headline ("9.6 pounds in 30 days") is based on 645 self-reported patient data points from Jan 2024 – Apr 2025 — self-reported data is lower-quality than a randomized trial
- ✗Broader wellness funnel (sermorelin + NAD+ + HRT alongside GLP-1s) means some patients may be upsold into off-weight-loss protocols — readers looking specifically for GLP-1 care should know the platform has a wider vertical mix
K Health
Pros
- ✓Established US telehealth with health-system integrations (Cedars-Sinai, Hartford HealthCare, Hackensack Meridian)
- ✓AI intake reduces upfront friction for users who don't want to sit through a long questionnaire before seeing a clinician
- ✓Primary-care relationship rather than a single-condition funnel — useful for users who want one provider managing multiple conditions
Cons
- ✗Not a GLP-1 specialty platform — weight management is ancillary to primary care, and GLP-1 prescribing is clinician-discretionary at the visit level
- ✗Pricing for GLP-1 specifically is not displayed publicly — needs direct confirmation from K Health support before placing readers
- ✗States served list and pharmacy partners are not publicly enumerated
Our Verdict
Get Thin MD edges out K Health with a higher overall score of 7.9/10 and is particularly strong for lowest-priced compounded semaglutide on a 3-month commitment, with brand-name Ozempic/Zepbound also available. K Health remains a solid alternative, especially if you're looking for users who want general primary care with GLP-1 prescribing as one available option, not a single-condition weight-loss funnel.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.